News | January 25, 2026
Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
This marks the second indication for which gumokimab has gained NDA review acceptance
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
Subscribe To Our Newsletter & Stay Updated
